Chemical Biology: Contribution to Molecular Therapeutic Innovation.
- Conjugates and Drug Discovery Chemistry: new challenges for targeted therapies –
MAS (Maison des Associations de Solidarité)
10 rue des terres au curé PARIS 13
December 7th, 2017
Aim of the symposium:
The aim of the symposium is to illustrate the great potential and the applications of conjugates in contributing to therapeutic innovation.
This meeting is dedicated to a large audience of organic and medicinal chemists, biochemists and biologists, and covers recent advances in the field of conjugates for therapeutic approaches, focusing on their preparation, evaluation and applications.
Recent development of conjugates offers new promises for the treatment of various diseases. In oncology, two antibody-drug conjugates (brentuximab vedotin and trastuzumab emtansine) are already approved for clinical use, and numerous conjugates are still in clinical evaluation. In addition to antibodies, other classes of vehicles like proteins, peptides, vitamins and polymers have been investigated for the selective delivery of drugs to malignant tissues. Conjugates also emerge for the development of new vaccines or appear as powerful tools to explore or manipulate living systems in chemical biology approaches.